Scientific Publications by Oryzon

At ORYZON we do cutting edge research in the oncological and neurodegenerative fields.


Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations. Maes T, et al. PLOS ONE, 2020, doi: 10.1371/journal.pone.0233468.

Vafidemstat: An epigenetic drug with emerging therapeutic potential, composite data from three psychiatric disorders from the REIMAGINE trial. Ramos-Quiroga JA, et al. International College of Neuropsychopharmacology International meeting, CINP 2019, poster communication.

Vafidemstat improves aggression scores in Autism: REIMAGINE, third cohort clinical data. Ropacki M, et al. 32th European College of Neuropsychopharmacology Congress, ECNP 2019, poster communication.

Safety Evaluation of Vafidemstat on Mild to Moderate Alzheimer’s Subjects. Bullock R, et al. Alzheimer’s Association International Conference, AAIC 2019, poster communication.

Vafidemstat is safe and effective in treating adult ADHD patients: Phase II REIMAGINE clinical trial. Bullock R, et al. 7th World Federation ADHD meeting 2019, poster communication.

Vafidemstat, a new approach to treat aggression in central nervous systems disorders: clinical study REIMAGINE. Report in a cohort of Borderline Personality patients. Ferrer M, et al. 27th European Congress of Psychiatry, EPA 2019, poster communication.

ETHERAL: Vafidemstat in Alzheimer’s disease: Design and baseline data. Bullock R, et al. 14th International Conference on Alzheimer’s and Parkinson’s Diseases, ADPD 2019, poster communication.

Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies. Ciceri F, et al. Curr Pharm Des. 2017; 23(5):839-857. doi: 10.2174/1381612823666170124121140. Review. PMID: 28120717

First-in-man Clinical Trial to Assess Safety, Tolerability and Pharmacokinetics of ORY-2001, a novel epigenetic drug for treatment of neurodegenerative diseases. Molinero C, et al. 13th International Conference on Alzheimer’s and Parkinson’s Diseases, ADPD2017, poster communication.

KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease Maes T, et al. Epigenomics, 2015 Jun;7(4):609-26. doi: 10.2217/epi.15.9 Review.


Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia, Deb G et al. Leukemia. 2019 Nov 28. doi: 10.1038/s41375-019-0659-6

CLEPSIDRA: a pilot, biomarker-guided study to assess safety, tolerability, dose finding and efficacy of iadademstat in combination with platinum-etoposide in patients with relapsed, extensive-stage small cell lung cancer. Navarro A, et al. European Society for Medical Oncology Congress, ESMO 2019, poster communication.

Iadademstat shows preliminary efficacy signals in relapsed ED-SCLC patients: A case report within CLEPSIDRA, a Phase II trial of iadademstat in combination with platinum-etoposide in biomarker-positive patients. Xaus J, et al. 20th World Conference on Lung Cancer, IASLC 2019, poster communication.

ALICE: An AML study with LSD1i in Combination with azacitidine in the Elderly. Montesinos P, et al. 24th Congress of the European Hematology Association, EHA 2019, poster communication.

ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. Maes T, et al. Cancer Cell. 2018 Mar 12;33(3):495-511.e12. doi: 10.1016/j.ccell.2018.02.002. Epub 2018 Mar 1. PMID: 29502954

Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of ORY-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study. Somervaille T, et al. Americal Society of Hematology Annual meeting, ASH 2016, poster communication.

KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease Maes T, et al. Epigenomics, 2015 Jun;7(4):609-26. doi: 10.2217/epi.15.9 Review.

Advances in the development of histone lysine demethylase inhibitors. Maes T, et al. Curr Opin Pharmacol. 2015 Jun 5;23:52-60. doi: 10.1016/j.coph.2015.05.009. Review. PMID: 26057211

Activity of highly selective LSD1 inhibitors in HCT-116 xenograft mice. Maes T, et al. Journal of Clinical Oncology, 2010 ASCO Annual Meeting Abstracts. Vol 28, No 15_suppl (May 20 Supplement), 2010: e13663

Other targets and diseases, & Technology

Discovery of a novel series of selective non-hydroxamic HDAC6 inhibitors, Salas J, et al. American Chemical Society meeting, ACS 2020, e-poster.

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays. Mascaró C, et al. J Vis Exp. 2019 Jun 13;(148). doi: 10.3791/59390.

Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable in vivo pharmacokinetics and -dynamics studies of KDM1A inhibitors. Mascaró C, et al. J. Biol. Chem. 2019 doi: 10.1074/jbc.RA118.006980. Epub 2019 Feb 25. PMID: 30804215

Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons. Rivers A, et al. Exp Hematol. 2018 Aug 17. pii: S0301-472X(18)30750-1. doi: 10.1016/j.exphem.2018.08.003. [Epub ahead of print] PMID: 30125603

Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer. Pio R, et al. BMC Genomics. 2010 Jun 3;11:352.

DNA Chip Technology in Brain Banks: Confronting a Degrading World. Buesa C, et al Journal of Neuropathology & Experimental Neurology, 2004 October - Volume 63 - Issue 10 - p 1003–1014